Skip to main content

Cardiol Therapeutics(CRDL-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low1.0000
Day High1.0600
Open:1.0600
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Cardiol Therapeutics

Select a category then submit the form to load news
Zacks Investment Research
Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards?
Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards?
Tipranks
Cardiol Therapeutics to Present Cardiovascular Pipeline Update at TD Cowen Health Care Conference
Newsfile
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference
Tipranks
Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL) and Centene (CNC)
Tipranks
Cardiol Therapeutics’ ARCHER Phase II Myocarditis Data Published in ESC Heart Failure
Newsfile
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure
Tipranks
Cardiol Therapeutics Secures $14.85 Million Bought-Deal Unit Financing
Tipranks
Cardiol Therapeutics Secures $13.5 Million Bought-Deal Financing to Advance Heart Disease Programs
Tipranks
Cardiol Therapeutics Raises $14.85 Million in Bought-Deal Financing to Support Late-Stage Heart Disease Programs
Newsfile
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million
Tipranks
Cardiol Therapeutics Secures $13.5 Million Bought Deal Financing to Advance Heart Disease Programs
Newsfile
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Tipranks
Cardiol Therapeutics Reaches 50% Enrollment in Pivotal Phase III MAVERIC Trial for Recurrent Pericarditis
Newsfile
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Tipranks
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
PressReach
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
Tipranks
Cardiol Therapeutics Reports Financial Challenges Amid Clinical Progress
Tipranks
Cardiol Therapeutics (CRDL) Gets a Buy from Canaccord Genuity
Tipranks
Cardiol Therapeutics Reports Q3 2025 Financial Results Amidst Cash Decrease
Tipranks
Cardiol Therapeutics Secures U.S. Patent for Heart Drugs
Newsfile
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
Newsfile
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
Tipranks
Cardiol Therapeutics Raises $16 Million Through Recent Securities Distribution
Tipranks
Cardiol Therapeutics Secures $11 Million to Advance Heart Disease Therapies
Tipranks
Canaccord Genuity Reaffirms Their Buy Rating on Cardiol Therapeutics (CRDL)
Tipranks
Cardiol Therapeutics Secures $11.4M Financing to Fund Heart Disease Therapies
Newsfile
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027
Tipranks
Cardiol Therapeutics Secures $11M Financing, Advances Heart Disease Therapies
Newsfile
Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027
Zacks Investment Research
Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics
Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics
Zacks Investment Research
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
Tipranks
Cardiol Therapeutics (CRDL) Has a New Rating from Brookline Capital Markets

Profile

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company's lead product consist CardiolRx(TM). Cardiol Therapeutics Inc. is based in Oakville, ON.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.